Chase Maureen, Robey Jennifer L, Zogby Kara E, Sease Keara L, Shofer Frances S, Hollander Judd E
Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
Ann Emerg Med. 2006 Sep;48(3):252-9. doi: 10.1016/j.annemergmed.2006.01.032. Epub 2006 Mar 20.
The Thrombolysis in Myocardial Infarction (TIMI) risk score is a 7-item tool derived from trials of patients with unstable angina/non-ST segment elevation myocardial infarction for risk stratification with respect to outcomes. It has been retrospectively evaluated in emergency department (ED) patients with potential acute coronary syndrome but has not been prospectively validated in this patient population. To validate the use of the TIMI risk score in the ED, we prospectively assess its potential utility in a broad ED chest pain patient population.
This was a prospective observational cohort study of consecutive ED chest pain patients enrolled from July 2003 until October 2004. Data included demographics, medical and cardiac history, and components of the TIMI risk score. Investigators followed the hospital course daily for admitted patients, and 30-day follow-up was performed on hospitalized and discharged patients. The main outcome was death, acute myocardial infarction, or revascularization as stratified by TIMI risk score at 30 days.
There were 1,481 eligible patient visits; 30-day follow-up was completed on 1,458 (98.4%) patients. Patients had mean age of 53.2+/-14 years and were 40% men, 66% black, and 30% white. Myocardial infarction occurred in 95 patients. The incidence of each TIMI risk factor was age greater than 65 years 21%, known coronary stenosis 18%, 3 or more risk factors 26%, ST-segment deviation 6%, 2 or more anginal events in the previous 24 hours 33%, aspirin use in the previous 7 days 35%, and elevated markers 6%. The incidence of 30-day death, acute myocardial infarction, and revascularization according to TIMI score is as follows: TIMI 0, 1.7% (95% confidence interval [CI] 0.42 to 2.95); TIMI 1, 8.2% (95% CI 5.27 to 11.04); TIMI 2, 8.6% (95% CI 5.02 to 12.08); TIMI 3, 16.8% (95% CI 10.91 to 22.62); TIMI 4, 24.6% (95% CI 16.38 to 32.77); TIMI 5, 37.5% (95% CI 21.25 to 53.75); and TIMI 6, 33.3% (95% CI 0 to 100). This relationship was highly significant.
Among ED patients with chest pain, the TIMI risk score does correlate with outcome. However, in our study the TIMI risk score failed to stratify these patients into discrete groups according to risk score. Also, patients with the lowest risk as defined by a TIMI score of zero had a 1.7% incidence of adverse events. Therefore, the TIMI risk score should not be used in isolation to determine disposition of ED chest pain patients.
心肌梗死溶栓(TIMI)风险评分是一种包含7个项目的工具,源自不稳定型心绞痛/非ST段抬高型心肌梗死患者的试验,用于对患者预后进行风险分层。该评分已在急诊科(ED)疑似急性冠状动脉综合征的患者中进行了回顾性评估,但尚未在该患者群体中进行前瞻性验证。为了验证TIMI风险评分在急诊科的应用价值,我们前瞻性地评估了其在广泛的急诊科胸痛患者群体中的潜在效用。
这是一项对2003年7月至2004年10月期间连续入组的急诊科胸痛患者进行的前瞻性观察队列研究。数据包括人口统计学信息、病史和心脏病史,以及TIMI风险评分的各项组成部分。研究人员每天跟踪住院患者的医院病程,并对住院和出院患者进行30天的随访。主要结局是30天时根据TIMI风险评分分层的死亡、急性心肌梗死或血运重建。
共有1481例符合条件的患者就诊;1458例(98.4%)患者完成了30天随访。患者的平均年龄为53.2±14岁,男性占40%,黑人占66%,白人占30%。95例患者发生了心肌梗死。各TIMI风险因素的发生率分别为:年龄大于65岁21%,已知冠状动脉狭窄18%,3个或更多风险因素26%,ST段偏移6%,前24小时内2次或更多次心绞痛发作33%,前7天内使用阿司匹林35%,标志物升高6%。根据TIMI评分的30天死亡、急性心肌梗死和血运重建发生率如下:TIMI 0为1.7%(95%置信区间[CI] 0.42至2.95);TIMI 1为8.2%(95% CI 5.27至11.04);TIMI 2为8.6%(95% CI 5.02至12.08);TIMI 3为16.8%(95% CI 10.91至22.62);TIMI 4为24.6%(95% CI 16.38至32.77);TIMI 5为37.5%(95% CI 21.25至53.75);TIMI 6为33.3%(95% CI 0至100)。这种关系具有高度显著性。
在急诊科胸痛患者中,TIMI风险评分与预后相关。然而,在我们的研究中,TIMI风险评分未能根据风险评分将这些患者分为不同的组。此外,TIMI评分为零定义的风险最低的患者不良事件发生率为1.7%。因此,不应单独使用TIMI风险评分来确定急诊科胸痛患者的处置。